EUVIMEDEUVIMED entdecken
Crossref

Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors

Luyu Ma, Mingzhe Zhong, Yingxuan Chang, Mingjin Luo, Xinyan Liu, Xiaofan Ge, Sitian Xu, Yun Zhang, Ziye Liu, Hua Xiang iD, Guoshun Luo iD

Journal of Medicinal Chemistry · 10.09.2026 · 69 (17) · 20651-20677

DOI: 10.1021/acs.jmedchem.6c01400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.08.2026. Verfasst von Luyu Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing211198,…. Hauptthemen laut MEDLINE: Poly (ADP-Ribose) Polymerase-1, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Jiangsu Provincial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual inhibition of Polθ and PARP1 represents a promising precision therapy strategy for HR-deficient tumors. While our first-generation Polθ/PARP1 dual inhibitor 4 provided proof-of-concept, its further development was hampered by poor selectivity over PARP2 and metabolic instability. Herein, we describe a structure-guided optimization that pioneers the integration of PARP1-selective pharmacophores. This effort culminated in the discovery of compound PP-048 (23), a second-generation dual inhibitor with single-digit nanomolar potency against Polθ and PARP1 (IC50 = 4.9 nM and 6.8 nM, respectively) and >226-fold selectivity over PARP2, PARP3, PARP5a/b, and PARP7. Notably, PP-048 displayed markedly improved hepatic stability and favorable oral systemic exposure. In an MDA-MB-436 xenograft model, PP-048 (10 mg/kg) achieved marked tumor growth inhibition (TGI = 91%) without eliciting the hematologic toxicity associated with PARP2 inhibition. To our knowledge, PP-048 represents the first reported PARP1-isoform-selective dual inhibitor, establishing a strategic foundation for development of this emerging class of inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly (ADP-Ribose) Polymerase-1Antineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsHumansAnimalsStructure-Activity RelationshipDNA Polymerase thetaCell Line, TumorMiceFemaleXenograft Model Antitumor Assays

Substanzen

Poly (ADP-Ribose) Polymerase-1Antineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsDNA Polymerase thetaPARP1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China.

ORCID-Profile: Hua Xiang, Guoshun Luo

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Jiangsu Provincial Department of Education

Zitieren

APA

Ma, L., Zhong, M., Chang, Y., Luo, M., Liu, X., Ge, X., Xu, S., Zhang, Y., Liu, Z., Xiang, H., & Luo, G. (2026). Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors. Journal of Medicinal Chemistry, 69(17), 20651-20677. https://doi.org/10.1021/acs.jmedchem.6c01400

Vancouver

Ma L, Zhong M, Chang Y, Luo M, Liu X, Ge X, et al. Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors. Journal of Medicinal Chemistry. 2026;69(17):20651-20677. doi:10.1021/acs.jmedchem.6c01400

BibTeX
@article{Ma2026,
  author = {Ma, Luyu and Zhong, Mingzhe and Chang, Yingxuan and Luo, Mingjin and Liu, Xinyan and Ge, Xiaofan and Xu, Sitian and Zhang, Yun and Liu, Ziye and Xiang, Hua and Luo, Guoshun},
  title = {Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {17},
  pages = {20651--20677},
  doi = {10.1021/acs.jmedchem.6c01400}
}
Kostenlos starten →